CCXI Description — ChemoCentryx, Inc.

ChemoCentryx is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. Co. targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the U.S., Co. markets TAVNEOS® (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis, and microscopic polyangiitis. Co. is also developing TAVNEOS for the treatment of severe Hidradenitis Suppurativa.

Company Name: 
ChemoCentryx, Inc.
Number of ETFs Holding CCXI: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   CCXI Weight   CCXI Amount 
 VTI   0.01%   $97,870,998         
 VB   0.08%   $84,133,965         
 XBI   1.13%   $77,178,975         
 IWM   0.15%   $71,873,839         
 VBK   0.19%   $49,891,780         
 VXF   0.04%   $34,443,965         
 IWO   0.21%   $18,792,610         
 VHT   0.05%   $10,012,800         
 IWN   0.08%   $8,611,263         
 VTWO   0.14%   $7,741,145         
List of all 34 ETFs holding CCXI »
Quotes delayed 20 minutes

Email EnvelopeFree CCXI Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Hold (2.00 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)

Analysts Forecast:
CCXI Price Target

Based on data provided by Zacks Investment Research via

ETFs Holding CCXI | ChemoCentryx, Inc. | ETF Channel |

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.